Tracer library / [223Ra]Ra-RaCl2
[223Ra]Ra-RaCl2
Also written as [Ra-223]RaCl2
- Radionuclide
- Ra-223 t½ 16459 min
- Modality
- Therapy
- Production route
- —
- Stage
- Approved
- Syntheses indexed
- 3
What it is
- Compound class
- bone-seeking radiopharmaceutical (radium dichloride, calcium-mimetic alpha emitter)
- Target / mechanism
- Calcium-mimetic alpha-emitter that localizes to bone metastases (bone-seeker) PMID 34163647
- Clinical application
- Treatment of bone metastases in metastatic castration-resistant prostate cancer PMID 36687439
- Theranostic pair
- —
Regulatory status
- FDA
- Yes — 2013; Xofigo (radium Ra 223 dichloride); sponsor BAYER HLTHCARE; NDA 203971 Drugs@FDA / openFDA drug registry, NDA 203971, original approval 2013-05-15, marketing status 'Prescription' — https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203971%22 (queried 2026-09-18)
- EMA (centralised)
- Yes — 2013; Xofigo (radium (223Ra) dichloride); Bayer AG; EMEA/H/C/002653 EMA medicines register (JSON export 2026-09-18), EPAR Xofigo: status 'Authorised', marketing authorisation date 2013-11-13 — https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo
- Other approvals
- —
- Brand names
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | 95 ± 1.05% | >95% | macropa | 34163647 2021 Chem Sci The reaction was carried out at room temperature by mixing a solution of macropa with 3.7 kBq (0.1 μCi) of [223Ra]Ra2+ - Within 5 min at room temperature, [223Ra][Ra(macropa)] was formed with a radiolabeling efficiency (RL% ± SD) of 95 ± 1.05% (n = 5) (Fig. 2a) |
| — | — | — | — | >94% | UiO-66-NH2 MOF (mMOF) | 41452472 2026 ACS Appl Mater Interfaces |
| — | — | — | — | >94% | UiO-66-NH2 MOF (nMOF) | 41452472 2026 ACS Appl Mater Interfaces |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience.2025 · Diagnostics (Basel) · Clinical study
- Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides.2022 · J Nucl Med Technol · Clinical study
- Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.2014 · Clin Cancer Res · Clinical study
Need this precursor?We can point you to suppliers for [223Ra]Ra-RaCl2, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 6 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 42149170: 'The radiopharmaceutical 223Ra-dichloride (Xofigo®) has been approved for palliative treatment of metastatic castration-resistant prostate cancer.'.